Results 1 to 10 of about 547 (137)

Targeted imaging of uPAR expression in vivo with cyclic AE105 variants [PDF]

Scientific Reports, 2023
A comprehensive literature reports on the correlation between elevated levels of urokinase-type plasminogen activator receptor (uPAR) and the severity of diseases with chronic inflammation including solid cancers.
Julie Maja Leth, Estella Anne Newcombe, Anne Louise Grønnemose, Jesper Tranekjær Jørgensen, Katrine Qvist, Anne Skovsbo Clausen, Line Bruhn Schneider Knudsen, Andreas Kjaer, Birthe Brandt Kragelund, Thomas Jørgen Dyreborg Jørgensen, Michael Ploug   +10 more
doaj   +9 more sources

Prospective phase II trial of [68Ga]Ga-NOTA-AE105 uPAR-PET/MRI in patients with primary gliomas: Prognostic value and Implications for uPAR-targeted Radionuclide Therapy [PDF]

EJNMMI Research
Background Treatment of patients with low-grade and high-grade gliomas is highly variable due to the large difference in survival expectancy. New non-invasive tools are needed for risk stratification prior to treatment.
Aleena Azam, Sorel Kurbegovic, Esben Andreas Carlsen, Thomas Lund Andersen, Vibeke André Larsen, Ian Law, Jane Skjøth-Rasmussen, Andreas Kjaer   +7 more
doaj   +7 more sources

Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression and [⁶⁴Cu]Cu-DOTA-AE105 uPAR-PET/CT in Patient-Derived Xenograft Models of Oral Squamous Cell Carcinoma. [PDF]

Mol Imaging Biol, 2023
Purpose [^64Cu]Cu-DOTA-AE105 urokinase-type plasminogen activator receptor (uPAR)-PET/CT is a novel and promising imaging modality for cancer visualization, although it has not been tested in head and neck cancer patients nor in preclinical models that ...
Lawaetz M, Binderup T, Christensen A, Juhl K, Lelkaitis G, Lykke E, Knudsen L, von Buchwald C, Kjaer A.   +8 more
europepmc   +6 more sources

Optimization and Evaluation of Al¹⁸F Labeling Using a NOTA-or RESCA1-Conjugated AE105 Peptide Antagonist of uPAR. [PDF]

Front Nucl Med, 2021
Fluorine-18 displays almost ideal decay properties for positron emission tomography (PET) and allows for large scale production. As such, simplified methods to radiolabel peptides with fluorine-18 are highly warranted.
Jeppesen TE, Simón M, Torp J, Knudsen LBS, Leth JM, Crestey F, Ploug M, Jørgensen JT, Madsen J, Herth MM, Kjaer A.   +10 more
europepmc   +7 more sources

Prospective Phase II Trial of Prognostication by ⁶⁸Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy. [PDF]

J Nucl Med, 2022
Visual Abstract The clinical course for patients with neuroendocrine neoplasms (NENs) ranges from indolent to highly aggressive. Noninvasive tools to improve prognostication and guide decisions on treatment are warranted.
Carlsen EA, Loft M, Loft A, Berthelsen AK, Langer SW, Knigge U, Kjaer A.   +6 more
europepmc   +6 more sources

Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105. [PDF]

PLoS ONE, 2016
Near infrared intra-operative optical imaging is an emerging technique with clear implications for improved cancer surgery by enabling a more distinct delineation of the tumor margins during resection.
Karina Juhl, Anders Christensen, Morten Persson, Michael Ploug, Andreas Kjaer   +4 more
doaj   +6 more sources

Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial [PDF]

Diagnostics, 2023
The detection of lymph node metastases is a major challenge in oral and oropharyngeal squamous cell carcinoma (OSCC and OPSCC). 68Ga-NOTA-AE105 is a novel positron emission tomography (PET) radioligand with high affinity to urokinase-type plasminogen ...
Mads Lawaetz, Anders Christensen, Karina Juhl, Giedrius Lelkaitis, Kirstine Karnov, Esben Andreas Carlsen, Birgitte W. Charabi, Annika Loft, Dorota Czyzewska, Christian von Buchwald, Andreas Kjaer   +10 more
doaj   +3 more sources

Novel Urokinase-Type Plasminogen Activator Receptor-Targeting Optical Imaging Agent ICG-Glu-Glu-AE105 for Visualization of Malignant Glioma During Surgery: First-in-Human Study in 35 Patients with Brain Cancer. [PDF]

Neurosurgery
BACKGROUND AND OBJECTIVES: Glioblastoma is an aggressive form of brain cancer for which surgery is the keystone in treatment before oncological treatment. Improving surgical resection without jeopardizing the outcome is eminent, and a fluorescent drug to
Skjøth-Rasmussen J, Azam A, Juhl K, Ginsborg S, Kryspin Sørensen M, Sølling C, Larsen CC, Winther Kristensen B, Scheie D, Kjaer A, Kjaer A.   +10 more
europepmc   +4 more sources

uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study [PDF]

Diagnostics, 2021
The aim of this Phase II study was to investigate the potential for response assessment and prognostication of positron emission tomography (PET) using the ligand 68Ga-NOTA-AE105 targeting the urokinase-type plasminogen activator receptor (uPAR) in ...
Marie Øbro Fosbøl, Jann Mortensen, Peter Meidahl Petersen, Annika Loft, Jacob Madsen, Andreas Kjaer   +5 more
doaj   +3 more sources

Tumor microenvironment-responsive metal nanotherapeutics for breast cancer chemo-/immunotherapy

NPG Asia Materials, 2023
Many metal complexes not only had excellent cytotoxic antitumor effects but also could function as a positive immunomodulatory to improve antitumor effects by modifying the local tumor microenvironment.
Jinggong Liu, Wenying Li, Yongpeng Lin, Yongjun Peng, Meixiao Zhan, Haoqiang Lai, Yanzhou Chang, Yongjin Li, Ka-hing Wong, Bolai Chen, Tianfeng Chen   +10 more
doaj   +2 more sources